Compare Cognizant Technology Solutions Corp (CTSH) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Quest Diagnostics Inc — how do they compare? Cognizant Technology Solutions Corp trades at $58.99 (market cap $26.40B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Cognizant Technology Solutions Corp and Quest Diagnostics Inc are close in size by market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| CTSH | DGX | |
|---|---|---|
Market Cap | $26.40B | $26.21B |
Sector | Technology | Health |
52-Week High | $86.70 | $238.50 |
52-Week Low | $38.73 | $173.49 |
Enterprise Value | $27.44B | $31.97B |
Dividend Yield | 2.25% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant (CTSH) trades at $58.19, down 0.21% today, with a bullish technical signal and strong cash flow. Recent Q2 2026 earnings missed estimates at $1.37 EPS, but revenue beat. The company maintains a solid net income margin of 10.26% and trades at a P/E of 12.58, below industry averages. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience amid AI-driven strategic shifts.
Outlook remains cautiously optimistic with upside potential from AI initiatives and financial services growth, though risks include client spending caution and competitive pressures. The stock's current valuation offers a margin of safety, but investors should monitor execution on AI integration and macroeconomic headwinds affecting IT spending.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
